title: Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.
abstract: Vascular endothelial growth factor (VEGF) is considered as a prime mediator of angiogenesis and has been implicated in carcinogenesis and metastasis. Various studies examined the relationship between VEGF overexpression with the clinical outcome in patients with osteosarcoma but yielded conflicting results. Electronic databases updated to April 2013 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between VEGF overexpression and survival of patients with osteosarcoma. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of eight studies that evaluated the correlation between VEGF overexpression and survival in patients with osteosarcoma. Combined hazard ratios suggested that VEGF overexpression had an unfavorable impact on overall survival (hazard ratio (HR) = 1.75, 95% confidence interval (CI): 1.21-2.28) in patients with osteosarcoma for overall populations, 2.37 (1.35-3.39) in Asian studies but not in non-Asian studies (HR = 1.51, 95% CI: 0.89-2.14). No significant heterogeneity was observed among all studies. VEGF overexpression indicates a poor prognosis for patients with osteosarcoma. However, the prognostic value of VEGF on survival in osteosarcoma patients still needs further large-scale prospective trials to be clarified.
authors.affiliation: Department of Orthopaedics, Shanghai Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200011, China.
authors.forename: Xiao-Wei
authors.initials: XW
authors.lastname: Yu
authors.forename: Tian-Yi
authors.initials: TY
authors.lastname: Wu
authors.forename: Xiang
authors.initials: X
authors.lastname: Yi
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Ren
authors.forename: Zu-bin
authors.initials: ZB
authors.lastname: Zhou
authors.forename: Yu-qiang
authors.initials: YQ
authors.lastname: Sun
authors.forename: Chang-qing
authors.initials: CQ
authors.lastname: Zhang
mesh_terms: D001859:Bone Neoplasms / Q000235:genetics* / Q000401:mortality*; D015870:Gene Expression; D006801:Humans; D012516:Osteosarcoma / Q000235:genetics* / Q000401:mortality*; D011379:Prognosis; D017594:Publication Bias; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: D042461:Vascular Endothelial Growth Factor A
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Mol Biol Rep. 2012 Oct;39(10):9473-84
references.pmid: 22729879
references.citation: Cancer. 2009 Nov 15;115(22):5243-50
references.pmid: 19670450
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1434-40
references.pmid: 15746043
references.citation: Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
references.pmid: 2858114
references.citation: Cytokine Growth Factor Rev. 2004 Oct;15(5):297-324
references.pmid: 15450248
references.citation: Orthopedics. 2005 Aug;28(8):755-60
references.pmid: 16119739
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Br J Cancer. 2009 May 5;100(9):1385-92
references.pmid: 19401698
references.citation: J Bone Joint Surg Br. 2009 Jun;91(6):784-8
references.pmid: 19483233
references.citation: Clin Cancer Res. 2000 Feb;6(2):572-7
references.pmid: 10690541
references.citation: Curr Med Chem. 2006;13(16):1845-57
references.pmid: 16842197
references.citation: Clin Orthop Relat Res. 2006 Jul;448:193-8
references.pmid: 16826116
references.citation: BMJ. 2001 Jul 28;323(7306):224-8
references.pmid: 11473921
references.citation: N Engl J Med. 2006 Dec 14;355(24):2542-50
references.pmid: 17167137
references.citation: J Clin Oncol. 2005 Feb 10;23(5):1011-27
references.pmid: 15585754
references.citation: Biometrics. 1994 Dec;50(4):1088-101
references.pmid: 7786990
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5018-22
references.pmid: 16951216
references.citation: Chin Clin Oncol. 2012 Dec;1(2):19
references.pmid: 25841397
references.citation: Br J Cancer. 2006 Jun 19;94(12):1823-32
references.pmid: 16773076
references.citation: BMC Cancer. 2010 Jun 02;10:252
references.pmid: 20525214
references.citation: Cancer Treat Res. 2009;152:289-308
references.pmid: 20213397
references.citation: Nat Rev Cancer. 2002 Oct;2(10):795-803
references.pmid: 12360282
references.citation: Mod Pathol. 2006 May;19(5):738-45
references.pmid: 16528367
references.citation: Cancer. 2006 Mar 1;106(5):1154-61
references.pmid: 16421923
references.citation: Pediatr Blood Cancer. 2011 Jul 15;57(1):63-8
references.pmid: 21416580
references.citation: Zhonghua Zhong Liu Za Zhi. 2012 Dec;34(12):899-904
references.pmid: 23336375
references.citation: Oncol Rep. 2006 Jul;16(1):17-23
references.pmid: 16786118
references.citation: J Clin Oncol. 1994 Feb;12(2):423-31
references.pmid: 8113851
references.citation: J Thorac Dis. 2013 Feb;5(1):40-7
references.pmid: 23372950
references.citation: Hematol Oncol Clin North Am. 2004 Oct;18(5):951-71, vii
references.pmid: 15474329
references.citation: Int J Oncol. 2000 Aug;17(2):291-5
references.pmid: 10891538
references.citation: Stat Med. 1998 Dec 30;17(24):2815-34
references.pmid: 9921604
references.citation: Hepatobiliary Surg Nutr. 2013 Jun;2(3):148-55
references.pmid: 24570933
references.citation: J Thorac Oncol. 2009 Sep;4(9):1094-103
references.pmid: 19687765
references.citation: Surg Oncol. 2011 Mar;20(1):13-9
references.pmid: 19836228
references.citation: Bull Exp Biol Med. 2010 Dec;150(2):237-42
references.pmid: 21240382
references.citation: Eur J Cancer. 1999 Jul;35(7):1089-93
references.pmid: 10533453